opidanz 50 mg 50 mg tabletki powlekane
pharma roth gmbh - opipramoli dihydrochloridum - tabletki powlekane - 50 mg
opipos 50 mg tabletki powlekane
pharma roth gmbh - opipramoli dihydrochloridum - tabletki powlekane - 50 mg
opiwar 100 mg 100 mg tabletki powlekane
pharma roth gmbh - opipramoli dihydrochloridum - tabletki powlekane - 100 mg
opiwar 50 mg 50 mg tabletki powlekane
pharma roth gmbh - opipramoli dihydrochloridum - tabletki powlekane - 50 mg
ivermectin medical valley 3 mg tabletki
medical valley invest ab - ivermectinum - tabletki - 3 mg
biopronil spot-on 402 mg/4,02 ml roztwór do nakrapiania
biowet drwalew sp. z o.o. - fipronilum - roztwór do nakrapiania - 402 mg/4,02 ml - pies
biopronil spot-on 67 mg/0,67 ml roztwór do nakrapiania
biowet drwalew sp. z o.o. - fipronilum - roztwór do nakrapiania - 67 mg/0,67 ml - pies
biopronil spot-on 134 mg/1,34 ml roztwór do nakrapiania
biowet drwalew sp. z o.o. - fipronilum - roztwór do nakrapiania - 134 mg/1,34 ml - pies
biopronil spot-on 268 mg/2,68 ml roztwór do nakrapiania
biowet drwalew sp. z o.o. - fipronilum - roztwór do nakrapiania - 268 mg/2,68 ml - pies
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.